Evidence map›Paper›PMID 30672659›Full record

ArticleESC heart failure2019

Determination of HLA-A, -B, -C, -DRB1 and -DQB1 allele and haplotype frequencies in heart failure patients.

Santiago Roura, Francesc Rudilla, Paloma Gastelurrutia, Emma Enrich, Eva Campos, Josep Lupón, Evelyn Santiago-Vacas, Sergi Querol, Antoni Bayés-Genís

Open access · goldAbstract read
In one paragraph

Article in ESC heart failure, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. HLA-DRB1Journal of oncology · 2021
    Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Santiago RouraICREC Research Program, Germans Trias i Pujol Health Science Research Institute, Badalona, Spain.
Francesc RudillaHistocompatibility and Immunogenetics Laboratory, Blood and Tissue Bank, Barcelona, Spain.
Paloma GastelurrutiaICREC Research Program, Germans Trias i Pujol Health Science Research Institute, Badalona, Spain.
Emma EnrichHistocompatibility and Immunogenetics Laboratory, Blood and Tissue Bank, Barcelona, Spain.
Eva CamposHistocompatibility and Immunogenetics Laboratory, Blood and Tissue Bank, Barcelona, Spain.
Josep LupónCIBER Cardiovascular, Instituto de Salud Carlos III, Madrid, Spain.
Evelyn Santiago-VacasCardiology Service, Germans Trias i Pujol University Hospital, Badalona, Spain.
Sergi QuerolTransfusional Medicine Group, Vall d'Hebron Research Institute, Autonomous University of Barcelona (UAB), Barcelona, Spain.
Antoni Bayés-GenísICREC Research Program, Germans Trias i Pujol Health Science Research Institute, Badalona, Spain.
Banc de Sang i Teixits · ESHospital Universitari Germans Trias i Pujol · ESInstitut d'Investigació en Ciències de la Salut Germans Trias i Pujol · ESUniversitat Autònoma de Barcelona · ESUniversitat de Barcelona · ESVall d'Hebron Institut de Recerca · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsCell therapy can be used to repair functionally impaired organs and tissues in humans. Although autologous cells have an immunological advantage, it is difficult to obtain high cell numbers for therapy. Well-characterized banks of cells with human leukocyte antigens (HLA) that are representative of a given population are thus needed. The present study investigates the HLA allele and haplotype frequencies in a cohort of heart failure (HF) patients. METHODS AND

resultsWe carried out the HLA typing and the allele and haplotype frequency analysis in 247 ambulatory HF patients. We determined HLA class I (A, B, and C) and class II (DRB1 and DQB1) using next-generation sequencing technology. The allele frequencies were obtained using Python for Population Genomics (PyPop) software, and HLA haplotypes were estimated using HaploStats. A total of 30 HLA-A, 56 HLA-B, 23 HLA-C, 36 HLA-DRB1, and 15 HLA-DQB1 distinct alleles were identified within the studied cohort. The genotype frequencies of all five HLA loci were in Hardy-Weinberg equilibrium. We detected differences in HLA allele frequencies among patients when the etiological cause of HF was considered. There were a total of 494 five-loci haplotypes, five of which were present six or more times. Moreover, the most common estimated HLA haplotype was HLA-A*01:01, HLA-B*08:01, HLA-C*07:01, HLA-DRB1*03:01, and HLA-DQB1*02:01 (6.07% haplotype frequency per patient). Remarkably, the 11 most frequent haplotypes would cover 31.17% of the patients of the cohort in need of allogeneic cell therapy.

conclusionsOur findings could be useful for improving allogeneic cell administration outcomes without concomitant immunosuppression.

Indexed as

AgedAllelesCell- and Tissue-Based TherapyFemaleGene FrequencyGenotypeHaplotypesHeart FailureHLA-A AntigensHLA-B AntigensHLA-C AntigensHLA-DQ beta-ChainsHLA-DRB1 ChainsHumansMaleHLA-A AntigensHLA-B AntigensHLA-C AntigensHLA-DQ beta-ChainsHLA-DRB1 ChainsAllele frequencyAllogeneic cell therapyHaplotype frequencyHeart failure

Identifiers

PMID30672659
PMCPMC6437550
OpenAlexW2914060362

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.